Belite Bio to Present at dbVIC - Deutsche Bank ADR Virtual Investor Conference

Strategic Insights -

Belite Bio, a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases, announced that Hao-Yuan Chuang, Chief Financial Officer, will present live at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference hosted by VirtualInvestorConferences.com. The conference is aimed at introducing global companies with ADR programs to investors. Hao-Yuan Chuang will present live on November 4th, 2025, at 10:30 am, and an archived webcast will be available after the event.

Key Takeaways:

  • Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases.
  • The company's lead candidate, Tinlarebant, is being evaluated in three Phase 3 studies: DRAGON for STGD1, DRAGON II for adolescent STGD1, and PHOENIX for GA in dry AMD.
  • Hao-Yuan Chuang, Chief Financial Officer, will present live at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 4th, 2025.
  • The conference is a virtual event where investors can ask questions in real-time, and an archived webcast will be available after the event.
  • Participation is free of charge, and online investors are recommended to pre-register and run the online system check to expedite participation.
  • Belite Bio has a presence on social media platforms, including Twitter, LinkedIn, and Facebook, and its website is (no website link provided).

Statistics:

  • Belite Bio's lead candidate, Tinlarebant, is being evaluated in three Phase 3 studies.
  • The company is focused on degenerative retinal diseases with significant unmet medical needs, such as STGD1 and GA in dry AMD.